



# WEEKLY WRAP-UP

22<sup>ND</sup> SEPTEMBER - 26<sup>TH</sup> SEPTEMBER 2025

**PROGRESSIVE**<sup>®</sup>  
Your Progress Our Priority...



## HIGHLIGHTS OF THE WEEK

22 Sept 2025-26 Sept 2025

### DOMESTIC:

- Pfizer closes in on USD7.3bn takeover of anti-obesity drugmaker Metsera: Report
- KEC International bags Rs3,243cr orders for transmission line, towers
- Adani Group plans leverage cut, sees no dollar bond issue until 2027
- Brigade Group inks 7.5-acre Banashankari project worth Rs1,200cr
- RVNL bags Rs1453mn Southern Railway project
- Torrent Power picks up stakes in Newzone India, its holding firm for Rs211cr
- Mazagon Dock Shipbuilders signs MoU with TN govt to develop greenfield shipyard on the eastern coast
- Pidilite bets on rising income, growth, urbanisation wave
- Swiggy Board approves sale of Rapido stake worth Rs2,400cr to Prosus, Westbridge Capital
- Tata-owned JLR delays factory reopening; plants shut till October
- Cochin Shipyard signs MoU with Korean shipbuilder, plans Rs3,700cr capex
- Jio BlackRock Mutual Fund targets consistency as it enters active arena
- ITC to continue Nepal investment plans in FMCG and hotels: Sanjiv Puri
- Vedanta's JAL deal puts govt stake in HZL, Balco at risk: US short-seller
- Dilip Buildcon wins Rs11.15bn Kerala industrial corridor project as lowest bidder
- HCLTech renews multi-year digital transformation deal with Swedish
- Lemon Tree launches Keys Lite by Lemon Tree Hotels, Krishna, Vijayawada
- ONGC, OIL aim to launch Rs3,200cr stratigraphic drilling campaign next year
- Reliance to invest Rs1,156cr in Thoothukudi FMCG manufacturing unit
- Bajaj Electricals to acquire Morphy Richards brand rights in India, region
- L&T, BEL join hands to support India's fifth-gen fighter aircraft programme
- Suzlon to transition entire vehicular fleet to electric vehicles by 2035
- Infosys expands partnership with Sunrise to modernise IT, boost AI adoption
- Zomato Hyperpure leases 2.5 lakh sq. ft. of warehousing space in Bhiwandi
- ACME Solar secures Rs1,100cr SBI funding for 300 MW project in Rajasthan
- JK Lakshmi Cement acquires 26% in Ampin C&I Power, commissions new grinding unit in Surat
- Glenmark inks pact with Hengrui Pharma for cancer therapy Trastuzumab Rezetecan
- Capri Global plans Rs6,500cr fundraise, to open 200 new branches

### ECONOMY:

- India GDP likely to grow at close to 7% in FY26 on GST boost: CEA Nageswaran
- SEBI, RBI to ease rules for Foreign Investors amid weak inflows, meet investors' delegation: Report
- Rupee hits all-time low of 88.75 against US dollar amid H-1B visa fee hike, foreign fund outflows

### INDUSTRY:

- Govt. looks to add 13GW hydro pumped storage projects annually from FY29 to meet 50GW target
- AC, TV dealers see spike in sales on day one as lower GST rate takes effect
- GST cut to save Rs1-1.5trn by 2030 for RE sector, says Pralhad Joshi

## HIGHLIGHTS OF THE WEEK

22 Sept 2025-26 Sept 2025

### COVERAGE NEWS:

**Zen Technologies Ltd:** The company's subsidiary Aituring Technologies Pvt. Ltd (ATPL) has allotted further equity shares through a private placement, reducing the company's holding to 49% in ATPL and consequently ATPL is now classified as an associate company.

**Indegene Ltd:** Datavant, the data collaboration platform trusted for healthcare, announced a strategic partnership with Indegene to enhance patient recruitment for clinical trials, with a focus on rare disease and other complex studies.

**Shilpa Medicare Ltd:** The company has received the initial authorization from European Medicine Agency (EMA), recommending the grant of the final marketing authorization for Rivaroxaban 10/15/20mg Orodispersible Films. The total Europe market for oral Rivaroxaban formulations is about USD2.5bn.

**Timken India Ltd:** The company has entered into a power purchase agreement to acquire 26.1% equity shares of Sunstreamgreen Energy C&I Three Pvt. Ltd for a cash consideration of approx. Rs7mn.

**Alkem Laboratories Ltd:** The company has launched Pertuza injection 420mg/14mL (a pertuzumab biosimilar) in India for the treatment of HER2-positive breast cancer.

**Remsons Industries Ltd:** The company expands in the NCR region by way of identification of an additional 80,000 sq. ft. property to support its expansion plans.

**Latent View Analytics Ltd:** The company has informed that based on the preliminary assessment and analysis of the US Executive Order related to fee increase for the H-1B visa applications and subsequent Memorandum issued by the USICS, the company doesn't anticipate any significant impact on its operations/financials.

**Torrent Pharmaceuticals Ltd:** The Competition Commission, South Africa has granted its approval to acquire controlling stake in J.B. Chemicals & Pharmaceuticals on 22nd Sept'25.

**Fineotex Chemical Ltd:** The company has scheduled a meeting to be held on 27th Sept 2025 in order to consider declaration of interim dividend, stock split and issuance of bonus shares, if any.

**Sterlite Technologies Ltd:** The company has showcased its advanced Unitube Single Jacket Indoor Fibre Optic Cable with 4-core Multi-Core Fiber (MCF) at Connected Britain 2025.

**Alembic Pharmaceuticals Ltd:** The company has received USFDA final approval for Paroxetine ER Tablets, 25/37.5mg.

**Supreme Petrochem Ltd:** The company has commissioned and commenced production of its first line of ABS with an installed capacity of 70000TPA at its Amdoshi plant.

### The Week That Went By:

The markets began the week on a subdued note, with bears gradually tightening their grip and pulling the Indices lower. With tariff terror back in action, the market sentiments dampened further, which was reflected with a freefall selling across the board on the last day of the week, and finally, Nifty50 settled the week at 24,654.70, marking a sharp decline of 672.35 points. All sectors closed in negative territory, with IT and Realty leading the losses. The real pressure was evident in the broader markets, where Midcaps and Smallcaps plunged 4.60% and 5.10%, respectively, significantly underperforming the Frontline Index.

Nifty50=24,654.70

Sensex30=80,426.46

Nifty Midcap 100=56378.55

Nifty Smallcap100=17560.90

## HIGHLIGHTS OF THE WEEK

22 Sept 2025-26 Sept 2025

### NIFTY (WEEKLY)



### BANK NIFTY (WEEKLY)



### MARKET OUTLOOK

The key resistance and support levels for **Nifty50** are placed at 24,900 and 24,550, respectively. For the **Bank Nifty**, 54,900 remains a significant hurdle on the upside, while support is seen at 54,070. As highlighted in the previous weekly notes, the **Auto** sector corrected sharply and formed a bearish engulfing pattern at record highs, signaling a trend reversal to negative. Similar bearish engulfing patterns were observed in the **Defence, Energy, and Realty** sectors. Meanwhile, the **IT** sector not only breached its previous swing support but also slipped below its 200WMA, reinforcing the bearish continuation. On the other hand, the **Metal and PSU Banking** indices have not shown any sign of reversal yet. Overall, the broader sectoral setup indicates a continuation of bearish momentum. However, with markets now in **extremely oversold territory** and the **monthly expiry** due next week, a technical pullback from lower levels cannot be ruled out, but the sustainability of any recovery at higher levels will be the key factor to watch.




## HIGHLIGHTS OF THE WEEK

22 Sept 2025-26 Sept 2025

### NIFTY 50 COMPONENTS (WEEKLY PERFORMANCE)

Adani Enterprises	0.30%	HDFC Life	(2.68%)	Reliance	(2.03%)
Adani Ports	(2.63%)	Hero Motocorp	(1.77%)	SBI Life	(2.41%)
Apollo Hospital	(3.74%)	Hindalco	(0.27%)	SBIN	(0.64%)
Asian Paints	(6.16%)	HUL	(2.03%)	ShriRam Finance	(4.19%)
Axis Bank	1.23%	ICICI Bank	(2.85%)	Sun Pharma	(4.40%)
Bajaj Auto	(2.91%)	IndusInd Bank	(4.30%)	Tata Consumer	(0.77%)
Bajaj Finserv	(3.26%)	INFY	(5.94%)	Tata Motors	(4.66%)
Bajaj Finance	(0.91%)	ITC	(1.22%)	Tata Steel	(2.69%)
BEL	(3.19%)	JioFin	(6.69%)	TCS	(8.38%)
Bharti Airtel	(2.27%)	JSW Steel	0.27%	Tech Mahindra	(9.63%)
Cipla	(4.81%)	Kotak Bank	(2.22%)	TITAN	(3.95%)
Coal India	(1.49%)	LT	1.60%	Trent	(7.65%)
Dr. Reddy's Labs	(5.14%)	M&M	(5.58%)	Ultratech	(3.36%)
Eicher Motors	0.78%	Maruti	2.69%	Wipro	(7.72%)
Eternal	(4.37%)	Nestle India	(2.96%)		
Grasim	(4.83%)	NTPC	(0.29%)		
HCL Tech	(5.10%)	ONGC	0.42%		
HDFC Bank	(2.35%)	PowerGrid	(1.53%)		

### SECTORAL PERFORMANCE





## HIGHLIGHTS OF THE WEEK

22 Sept 2025-26 Sept 2025

### DISCLAIMERS AND DISCLOSURES-

Progressive Share Brokers Pvt. Ltd. and its affiliates are a full-service, brokerage and financing group. Progressive Share Brokers Pvt. Ltd. (PSBPL) along with its affiliates are participants in virtually all securities trading markets in India. PSBPL started its operation on the National Stock Exchange (NSE) in 1996. PSBPL is a corporate trading member of Bombay Stock Exchange Limited (BSE), National Stock Exchange of India Limited (NSE) for its stock broking services and is Depository Participant with Central Depository Services Limited (CDSL) and is a member of Association of Mutual Funds of India (AMFI) for distribution of financial products.

PSBPL is SEBI registered Research Analyst under SEBI (Research Analysts) Regulations, 2014 with SEBI Registration No. INH000000859/Research Analyst BSE Enlistment No. 5049. PSBPL hereby declares that it has not defaulted with any stock exchange nor its activities were suspended by any stock exchange with whom it is registered in last five years. PSBPL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

PSBPL offers research services to clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Other disclosures by Progressive Share Brokers Pvt. Ltd. (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company (s) covered in this report:-

- PSBPL or its associates financial interest in the subject company: NO
- Research Analyst (s) or his/her relative's financial interest in the subject company: NO
- PSBPL or its associates and Research Analyst or his/her relative's does not have any material conflict of interest in the subject company. The research Analyst or research entity (PSBPL) has not been engaged in market making activity for the subject company.
- PSBPL or its associates actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report: NO
- Research Analyst or his/her relatives have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report: NO
- PSBPL or its associates may have received any compensation including for brokerage services from the subject company in the past 12 months. PSBPL or its associates may have received compensation for products or services other than brokerage services from the subject company in the past 12 months. PSBPL or its associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research report. Subject Company may have been client of PSBPL or its associates during twelve months preceding the date of distribution of the research report and PSBPL may have co-managed public offering of securities for the subject company in the past twelve months.
- The research analyst has served as officer, director or employee of the subject company: NO
- Registration granted by SEBI and certification from NISM is in no way guarantee performance of the intermediary or provide any assurance of returns to investors

PSBPL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. Our sales people, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses (if any) may make investment decisions that may be inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution publication, availability or use would be contrary to law or regulation or which would subject PSBPL or its group companies to any registration or licensing requirement within such jurisdiction. If this document is sent or has reached any individual in such country, especially, USA, the same may be ignored. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of PSBPL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of PSBPL or its Group Companies. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

### Terms & Conditions:

This report has been prepared by PSBPL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of PSBPL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and its at discretion of the clients to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. PSBPL will not treat recipients as customers by virtue of their receiving this report.

### Registered Office Address:

Progressive Share Brokers Pvt. Ltd,  
122-124, Laxmi Plaza, Laxmi Indl Estate,  
New Link Rd, Andheri West,  
Mumbai—400053, Maharashtra  
www.progressiveshares.com | Contact No.:022-40777500.

### Compliance Officer:

Ms. Neha Oza,  
Email: compliance@progressiveshares.com,  
Contact No.:022-40777500.

### Grievance Officer:

Email: grievancecell@progressiveshares.com